Hikal Limited
NSE: HIKALMarket Closed • NSE
Day range
52 week range
Hikal Limited closed at INR215.64 (-0.38%) on volume 0.36x its 20-day average, trading 17.38% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -151.4% QoQ
2026-09-04
DIVIDEND Announced
Dividend - Re 0.40 Per Share
2026-02-17
DIVIDEND Announced
Interim Dividend - Re 0.20 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Established operational history in the sector
Active institutional participation
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 04 Sept 2026 | Dividend | ₹0.40 / share | — | 04 Sept 2026 |
| 17 Feb 2026 | Dividend | ₹0.20 / share | — | 17 Feb 2026 |
| 02 Sept 2025 | Dividend | ₹0.80 / share | — | 02 Sept 2025 |
| 08 Feb 2025 | Dividend | ₹0.60 / share | — | 07 Feb 2025 |
| — | Annual General Meeting | Annual General Meeting | — | 10 Sept 2024 |
| 04 Sept 2024 | Dividend | ₹0.60 / share | — | 04 Sept 2024 |
| 20 Feb 2024 | Dividend | ₹0.60 / share | — | 20 Feb 2024 |
| — | Dividend | ₹0.60 / share | — | 18 Sept 2023 |
| 14 Feb 2023 | Dividend | ₹0.60 / share | — | 14 Feb 2023 |
| 15 Sept 2022 | Dividend | ₹0.40 / share | — | 14 Sept 2022 |
| — | Annual General Meeting | Annual General Meeting | — | 14 Sept 2022 |
| 24 Feb 2022 | Dividend | ₹1.20 / share | — | 23 Feb 2022 |
| 26 Aug 2021 | Dividend | ₹1.00 / share | — | 25 Aug 2021 |
| 16 Feb 2021 | Dividend | ₹1.00 / share | — | 15 Feb 2021 |
| — | Dividend | ₹0.20 / share | — | 07 Sept 2020 |
| 18 Feb 2020 | Dividend | ₹1.00 / share | — | 17 Feb 2020 |
| — | Dividend | ₹0.60 / share | — | 23 Jul 2019 |
| 14 Feb 2019 | Dividend | ₹0.60 / share | — | 13 Feb 2019 |
| — | Dividend | ₹0.50 / share | — | 31 Jul 2018 |
| 25 Jun 2018 | Bonus issue | 1:2 bonus ratio | — | 22 Jun 2018 |
| 22 Feb 2018 | Dividend | ₹0.70 / share | — | 21 Feb 2018 |
| — | Dividend | ₹0.60 / share | — | 02 Aug 2017 |
| 14 Feb 2017 | Dividend | ₹0.60 / share | — | 13 Feb 2017 |
| — | Dividend | ₹0.50 / share | — | 02 Aug 2016 |
| 18 May 2016 | Dividend | ₹0.50 / share | — | 17 May 2016 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates for its customers. Hikal's manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad {Maharashtra). The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal's R & D facilities are located in Pune.[1]
IndiaHealthcare
Is Hikal Limited Shariah compliant?
Hikal Limited is currently screened as Non-Compliant (Financial Ratios) under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (57.04%) exceeds AAOIFI threshold (≤ 33%).
What is Hikal Limited's current valuation relative to peers?
Hikal Limited trades at a P/E of N/A compared to the sector median of 37x, and a Price-to-Book of 2.2x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.57x. Interest coverage is comfortable.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at -0.2% while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.